Back to journals
Academic Journal

Psychopharmacology

104 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)

This open-label trial (n=25) found that six weeks of low-dose oral ketamine treatment for PTSD was associated with small but significant decreases in both BDNF and VEGF-A blood biomarkers, which were positively correlated with each other, suggesting these two proteins may interact as part of the biological mechanism behind ketamine's effects on PTSD symptoms.

Published
Journal
Psychopharmacology
Authors
Quigley, B. L., Orr, E., Kafka, S., Hajishafiee, M., Bouças, A. P., Wellington, N., Dutton, M., Jones, M., Randall, F., Lagopoulos, J., Can, A. T., Hermens, D. F.
Open Accessindividual

Intact neurophysiological markers of death denial in long-term ayahuasca users

Using a no‑report MEG visual mismatch response paradigm, the study found that long‑term ayahuasca users report reduced fear of death and greater life satisfaction, but nonetheless retain intact neurophysiological markers of self‑specific death denial at automatic perceptual levels. The neural denial marker correlated with lower self‑reported death acceptance and reduced accessibility of death‑related thoughts, suggesting ayahuasca alters conceptual and affective engagement with death but not unconscious self‑specific denial.

Published
Journal
Psychopharmacology
Authors
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A.
Paywallindividual

The effect of methamphetamine and 3,4-methylenedioxymethamphetamine on peripheral endocannabinoid concentrations: a study in healthy adults

This within-subject, double-blind study (n=22) found that acute administration of methamphetamine (14 mg/70 kg) significantly lowered plasma 2-arachidonoylglycerol concentrations compared to placebo at 150-180 minutes post-administration, whilst MDMA (100 mg) did not affect endocannabinoid levels, and higher anandamide concentrations during the placebo condition correlated with disliking the 'drug effects'.

Published
Journal
Psychopharmacology
Authors
Mayo, L. M., Haggarty, C. J., Petrie, S. R., Hill, M. N., Bershad, A. K., de Wit, H., Deutch, A. Y.
Open Accessindividual

Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation

In a naturalistic, open‑label study a single high dose of psilocybin with psychotherapy produced sustained reductions in depression, anxiety, PTSD symptoms and neuroticism, and increases in openness and conscientiousness at three months. The size of these benefits was moderated by participants’ subjective dosing experiences (mystical‑type experiences, emotional breakthrough and post‑treatment growth) and demographic factors, highlighting variables that may help optimise psilocybin‑assisted treatment.

Published
Journal
Psychopharmacology
Authors
Irrmischer, M., Puxty, D. J., Deijen, J. B., Engelbregt, H., Yildirim, B. O.
Open Accessmeta

Practical considerations in the establishment of psychedelic research programs

This perspective article (2024) for investigators at academic medical centres in the United States provides recommendations for establishing psychedelic research programs. It highlights challenges including funding, regulatory approvals, sourcing controlled substances, preparing study spaces, managing controlled substances, and engaging the local community, and offers strategies to anticipate and surmount these obstacles.

Published
Journal
Psychopharmacology
Authors
Murnane, K. S., Barnett, B. S., Vest, •. M. F., Delatte, M. S., King, F., Mauney, E. E., Coulson, A. J., Nayak, S. M., Hendricks, P. S., Greer, G. R.
Paywallindividual

Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey

This online survey (n=233) of autistic participants with high autism quotient scores examines their experiences with psychedelic drugs and perceived changes attributed to their most 'impactful' psychedelic experience. It finds that the majority of participants reported reductions in psychological distress (82%) and social anxiety (78%), and increases in social engagement (70%), while 20% reported undesirable effects such as increased anxiety.

Published
Journal
Psychopharmacology
Authors
Stroud, J., Rice, C., Orsini, A., Schlosser, M., Lee, J., Mandy, W., Kamboj, S. K.

Quick Facts

Papers Indexed
104
h-Index
218
Open Access
No
Publisher
Springer Nature
Country
Germany
Website
Visit